Tweet

BioVeteria Licenses Regenerative Technology For Cartilage And Bone

Author: BioVeteria Life Sciences, LLC
Posted: Wednesday 20th July, 2011. 09:53:33

BioVeteria's exclusive license covers an orally active cartilage and bone regeneration technology licensed for the multi-billion dollar animal health industry

BioVeteria Life Sciences, LLC (BioVeteria), a privately held veterinary bioscience company, announced they have exclusively licensed a patented, orally active cartilage and bone repair technology from the Canadian Arthritis Network (CAN). This technology has shown the ability to stimulate cartilage cell proliferation, enhance bone repair, and preserve cartilage and bone architecture in severe models of arthritis. Arthritis, osteochondrosis dessicans, fracture repair, bone cysts, and navicular disease are common disorders in veterinary medicine. BioVeteria plans on evaluating this new technology for a variety of orthopedic conditions in need of better and more effective strategies. License details were not disclosed.

Craig Woods DVM, MS, MBA, general manager for BioVeteria stated, "We are very excited to be working with CAN on this new technology. The technology represents a significant advancement in veterinary orthopedics and proposes to improve our understanding on new techniques for cartilage and bone regeneration. In addition, our comparative work in dogs and horses will benefit our understanding for human medicine."

Johnathan Riley, Managing Director of the Canadian Arthritis Network, says "CAN is very pleased to be working with BioVeteria to bring Dr. Anastassiades' ANABUTM technology to market. Dr. Anastassiades has performed extensive research that has demonstrated striking benefits of ANABUTM in arthritis and osteoporosis animal models."

The technology was discovered and developed by Tassos Anastassiades, MD, PhD, a leading expert in glucosamine derivatives in arthritis and bone-related diseases. The technology is an optimized glucosamine derivative, having shown significantly better effects on cartilage and bone systems when compared to glucosamine. The lead compound has been extensively evaluated in vitro and in vivo, and is the subject of publications in the Journal of Rheumatology and Journal of Pharmacology and Experimental Therapeutics.

This article has been viewed 992 times.

 

Comments about this article